

May 20, 2011

Dear Mark:

We are writing to thank you for your significant contributions to the COU-AA-301 study, the rapid submission of high-quality dossiers in the US and EU, and the recent approval of ZYTIGA™ in the US. We recognize especially your tremendous diligence, focus, and teamwork. Your belief and determination in demonstrating the benefit that ZYTIGA can provide patients has resulted in a significant step forward for men with metastatic castration-resistant prostate cancer.

It may seem at times that your job is all about an insurmountable volume of emails, extremely long days, and last-minute meetings, and we realize that on this project you were asked to work under great pressure and often late into the night and on weekends. However, the truth is that your outstanding effort and hard work bring real value to patients. The approval of ZYTIGA is a major milestone for Ortho Biotech Oncology Research & Development, for Pharma R&D, and for J&J as a whole. It brings us closer to our vision of transforming cancer to a chronic or curable disease by delivering extraordinary diagnostic and therapeutic solutions that prolong and improve patients' lives.

We hope that you will share this achievement with your family and friends and also thank them for their understanding and support. We realize that the sacrifices you have made are also borne by them.

In addition to this note of recognition, you will receive a certificate signifying the award and a financial reward that will appear in your paycheck(s) shortly. This monetary reward further recognizes your contributions to our patients, our health care provider customers, and our company and our belief that you went well above and beyond the norms of your job in helping achieve this success.

With respect and gratitude,



Michael L. Meyers, M.D., Ph.D.